Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
17 decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
17 decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
5601
-
5602
-
5603
-
5604
Image 3_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff
Published 2025“…</p>Results<p>Of these, 17 patients received tocilizumab, resulting in a significant reduction in the duration of grade 3 CRS compared to those who did not receive the drug. …”
-
5605
Table 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.docx
Published 2025“…</p>Results<p>Of these, 17 patients received tocilizumab, resulting in a significant reduction in the duration of grade 3 CRS compared to those who did not receive the drug. …”
-
5606
Image 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff
Published 2025“…</p>Results<p>Of these, 17 patients received tocilizumab, resulting in a significant reduction in the duration of grade 3 CRS compared to those who did not receive the drug. …”
-
5607
Table 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.doc
Published 2025“…</p>Results<p>Of these, 17 patients received tocilizumab, resulting in a significant reduction in the duration of grade 3 CRS compared to those who did not receive the drug. …”
-
5608
Image 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff
Published 2025“…</p>Results<p>Of these, 17 patients received tocilizumab, resulting in a significant reduction in the duration of grade 3 CRS compared to those who did not receive the drug. …”
-
5609
Source Apportionment of Atmospheric Iron in Northern China Based on Three-Year Continuous Measurements
Published 2025“…Results showed nearly 50% of Fe originated from anthropogenic sources, primarily industrial processes (30%) and coal combustion (17%). Although PM<sub>2.5</sub> concentrations decreased significantly, the Fe component of PM<sub>2.5</sub> did not show a significant decline. …”
-
5610
-
5611
-
5612
-
5613
-
5614
-
5615
-
5616
-
5617
-
5618
Supplementary file 1_Analysis of gut and circulating microbiota characteristics in patients with liver cirrhosis and portal vein thrombosis.docx
Published 2025“…</p>Results<p>(1) Gut microbiota showed no α-diversity difference between groups, but β-diversity differed significantly. PVT patients had increased Gram-negative bacteria (such as Escherichia-Shigella) and decreased SCFA-producing taxa. (2) Compared with peripheral vein microbiota, portal vein microbiota showed significant difference in α diversity and β diversity in cirrhotic patients with PVT, with Massilia enriched. (3) Portal microbiota had the highest diagnostic value for PVT (AUC = 0.95). (4) The tPVT group had more portal-feces shared genera than the tNPVT group (49 vs. 29). …”
-
5619
-
5620